Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP®
- PMID: 29556960
- DOI: 10.1007/s40259-018-0272-7
Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP®
Abstract
Background: For regulatory approval, the comparability of a biosimilar product to an originator product should be ensured through thorough physicochemical and biological characterization.
Objective: To evaluate the biosimilarity between LBDE, the proposed biosimilar darbepoetin alfa, and NESP®, its originator, we performed a comprehensive physicochemical and biological characterization study.
Methods: Primary and higher-order protein structures were analyzed using Lys-C peptide mapping with liquid chromatography-mass spectrometry (LC-MS), disulfide bond identification, circular dichroism, and fluorescence spectroscopy. Glycosylation and isoform distribution were analyzed using MS, LC, and capillary zone electrophoresis. Size variants were evaluated with size-exclusion chromatography-high-performance liquid chromatography (SEC-HPLC) and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Biological characterization included binding affinity for human erythropoietin receptor, in vitro cell proliferation, and in vivo potency. Pharmacokinetics (PK) were evaluated using rats through two injection routes.
Results: Non-reducing and reducing Lys-C peptide mapping showed a highly similar peak profile, confirming that LBDE and NESP® have the same primary structure and disulfide bonds. Glycosylation and isoform analyses showed that the attached N-glycan and O-glycan structures were the same and their relative contents were similar. Spectroscopic analysis of LBDE showed indistinguishable spectra with NESP®. For both LBDE and NESP®, a very small amount of size variants was found in SEC-HPLC, and no minor bands were detected in SDS-PAGE. Furthermore, LBDE did not show any difference with NESP® in the in vitro and in vivo functional analyses. PK parameters of LBDE were in good agreement with those of NESP®.
Conclusion: LBDE shows high similarity to NESP® with regard to structure and function.
Similar articles
-
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.PLoS One. 2020 Apr 17;15(4):e0231830. doi: 10.1371/journal.pone.0231830. eCollection 2020. PLoS One. 2020. PMID: 32302352 Free PMC article.
-
Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.BioDrugs. 2013 Oct;27(5):495-507. doi: 10.1007/s40259-013-0036-3. BioDrugs. 2013. PMID: 23649935 Free PMC article.
-
Mass spectrometric characterisation of darbepoetin alfa biosimilars with C-terminal arginine residues.Drug Test Anal. 2016 Nov;8(11-12):1138-1146. doi: 10.1002/dta.2102. Epub 2016 Nov 4. Drug Test Anal. 2016. PMID: 27706921
-
Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16. Expert Opin Biol Ther. 2016. PMID: 27463856 Review.
-
Development and characterization of novel erythropoiesis stimulating protein (NESP).Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):3-10. doi: 10.1054/bjoc.2001.1746. Br J Cancer. 2001. PMID: 11308268 Free PMC article. Review.
Cited by
-
Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.PLoS One. 2020 Apr 17;15(4):e0231830. doi: 10.1371/journal.pone.0231830. eCollection 2020. PLoS One. 2020. PMID: 32302352 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources